CAS: 139481-41-7; Ethyl 1-((2'-Cyano-[1,1'-Biphenyl]-4-yl)Methyl)-2-Ethoxy-1H-Benzo[d]Imidazole-7-Carboxylate

相似化合物

139481-44-0 632322-61-3 147403-65-4

上下游产品

CAS号863031-21-4 阿齐沙坦奥美沙坦酯 | CAS号139481-58-6 坎地沙坦乙酯 | CAS号147403-03-0 阿齐沙坦 | CAS号147403-52-9 1-[(2'-[(乙氧羰基)氧...

2-羧基-3-硝基苯甲酸乙酯置于氯化亚砜,Sodium Azide,Tin(II) Chloride Dihdyrate,Sodium Hydride,溶剂黄146体系中,化学反应 4.0H,反应生成2-乙氧基-1-[[(2'-腈基连苯-4-取代)甲基]苯并咪唑]-7-羧酸乙酯
参考文献:Synthesis,Characterization Of Benzimidazole Carboxamide Derivatives As Potent Anaplastic Lymphoma Kinase Inhibitor And Antioxidant Activity
标题:Synthesis,Characterization Of Benzimidazole Carboxamide Derivatives As Potent Anaplastic Lymphoma Kinase Inhibitor And Antioxidant Activity
摘要:Novel Benzimidazole Carboxamide Derivatives Have Been Synthesized And Characterized By Ftir,NMR,And Mass Spectral Analysis. The Synthesized Compounds 7A,7D,And 7F Showed Excellent Scavenging Capacity Against Dpph Radical And The Results Are Comparable With Ascorbic Acid. In-Silico Molecular Docking Studies Exhibited Compounds 7A,7D,And 7F Had A Good Affinity Towards The Active Pocket And The Results Indicated The Ability Of Potent And Selective Inhibition Of Anaplastic Lymphoma Kinase (Alk) Receptor. The Theoretical Investigation Of Meps,Homo,Lumo,And The Energy Gap Of Homo-Lumo Were Calculated By B3Lyp/6-31G Method And Reactivity Descriptors Were Also Computed.[graphics]
Doi:10.1080/00397911.2018.1554144

专利信息

专利号:US-8143435-B2
优先权日:2006-10-10
标题:One pot process for the preparation of candesartan
发明人：OM DUTT TYAGI; KARUSALA NAGESWARA RAO; TUMMALAPALLI UMA SANKARA SASTRY; BANDARI MOHAN; GORANTLA SEETA RAMANJANEYULU
权利人:OM DUTT TYAGI; KARUSALA NAGESWARA RAO; TUMMALAPALLI UMA SANKARA SASTRY; BANDARI MOHAN; GORANTLA SEETA RAMANJANEYULU; MYLAN LAB LTD
摘要:Present invention is to provide one pot synthesis of candesartan without isolating the ester intermediate.

专利号:US-7884212-B2
优先权日:2005-10-07
标题 :Process for the preparation of candesartan cilexetil
发明人：ZUPANCIC SILVO
权利人:ZUPANCIC SILVO
摘要:The present invention provides an improved synthesis for the manufacture of candesartan and pharmaceutically acceptable salts and esters thereof as active ingredients of a medicament for the treatment of hypertension and related diseases and conditions which comprises the removal of the tetrazolyl protecting group in an organic solvent, and in the presence of a Lewis acid.